US Patent Issued to Eli Lilly and Co. on Feb. 24 for "CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas" (Indiana Inventor)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,558,345, issued on Feb. 24, was assigned to Eli Lilly and Co. (Indianapolis).

"CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas" was invented by Louis Frank Stancato (Fishers, Ind.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile and pharmaceutically acceptable salts and solvates thereof, that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas."

The patent was filed on Aug. 15, 2021, under Application No. 17/402,564.

*For further information, ...